Identifying approaches to reduce IRRs with IV amivantamab
Gilberto Lopes, Associate director for global oncology and interim chief for the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared a post by Mark Wildgust, Vice President of Oncology Global Medical Affairs at Johnson and Johnson, on X:
“An important part of the job is to improve the safety and tolerance profile of innovative drugs. Thank you J and J Innovative Medicine, for the opportunity to participate in and present this study at WCLC24. Join us!”
Quoting for Mark Wildgust‘s post:
“Really proud of my J and J Innovative Medicine Oncology Global Medical Affairs team who led the worldwide SKIPPirr study to identify approaches to reduce IRRs with IV amivantamab. WCLC24 abstract below!
Authors: Gilberto Lopes, A.I. Spira, J-Y. Han, J-Y. Shih, C. Mascaux, U. Basu Roy, J. Zugazagoitia, Y.J. Kim, C-H. Chiu, S-W. Kim, E. Nadal, I. Gil-Bazo, S. Murphy, P. Mahadevia, B.G. Anderson, K. Xia, G. Wang, J.M. Bauml, M. Chioda, J. Simoes, L. Paz-Ares
Source: Gilberto Lopes/X and Mark Wildgust/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023